Sanofi Halts Clinical Program In ADPKD As Venglustat Trial Failed To Meet Futility Criteria

French drug maker Sanofi (SNY) announced Tuesday that a pivotal Phase 2/3 study of venglustat in autosomal dominant polycystic kidney disease or ADPKD did not meet futility criteria, and the company has halted the clinical program in ADPKD.

The company noted that the safety profile of venglustat remains consistent with previously reported results. More than 500 patients were treated to date over a period of up to four years across all clinical programs. Biomarker data from the study confirmed venglustat effectively inhibits the glycosphingolipid or GSL pathway by demonstrating a reduction in GL-1, a lipid that accumulates in certain cells.

According to the company, the STAGED-PKD study was stopped for futility following an independent analysis of the annualized rate of change in total kidney volume or TKV in patients receiving venglustat compared to placebo.

Trends from the analysis showed venglustat did not provide a meaningful reduction in TKV growth rate, the primary endpoint of stage 1 of the Phase 2/3 study. This interim analysis suggests the reduction of GSLs may not play a significant role in the prevention of kidney cyst growth, and as such, may not be a primary pathway associated with the progression of ADPKD.

Sanofi said the investigational research of venglustat in ADPKD was an attempt to explore a novel biological role for GSLs beyond the established role of these lipids in lysosomal storage diseases or LSDs.

John Reed, Global Head of Research and Development at Sanofi,said, “The venglustat development program started with our confidence in the promise of a potential breakthrough treatment to address the unmet needs of people living with lysosomal storage disorders. In parallel, weset out to evaluatevenglustatin autosomal dominant polycystic kidney disease, a leading cause of kidney transplant. This outcome is not what we hoped for, especially for these patients. However, our research has furthered the scientific understanding of ADPKD by demonstrating that modulating the GSL pathway is insufficient to restore kidney function in adults affected by this disease.”

Source: Read Full Article